Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ.
Bobkov V, et al. Among authors: bialkowska m.
Biochem Pharmacol. 2018 Dec;158:413-424. doi: 10.1016/j.bcp.2018.10.014. Epub 2018 Oct 17.
Biochem Pharmacol. 2018.
PMID: 30342023
Free article.